Quantcast

Latest Lamotrigine Stories

2014-09-01 00:21:00

- VIMPAT® (lacosamide) C-V approved in the U.S. as monotherapy in the treatment of partial-onset seizures in adults with epilepsy(1) BRUSSELS, Sept. 1, 2014 /PRNewswire/ -- 0700 (CEST) - regulated information -- UCB announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for VIMPAT(®) (lacosamide) C-V as monotherapy in the treatment of partial-onset seizures in patients with epilepsy aged 17 years and older.(1) This is a new...

2014-07-18 23:01:32

Transparency Market Research added a new report "Global Epilepsy Therapeutics Market: Industry Analysis, Size, Share, Growth and Forecast 2019" to its report store. Browse the full report: http://www.transparencymarketresearch.com/epilepsy-therapeutics-market.html. (PRWEB) July 18, 2014 Epilepsy is a group of long-term neurological disorders that is characterized by recurring seizures. These seizures are episodes that occur when group of nerve cells or neurons in brain sends...

2014-07-15 16:27:31

LONDON, July 15, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Epilepsy Therapeutics in Major Developed Markets to 2019 - New AEDs with Novel Mechanisms of Action Signal a Shift in Treatment Patternshttps://www.reportbuyer.com/product/2052297/Epilepsy-Therapeutics-in-Major-Developed-Markets-to-2019---New-AEDs-with-Novel-Mechanisms-of-Action-Signal-a-Shift-in-Treatment-Patterns.htmlEpilepsy Therapeutics in Major Developed Markets to 2019 - New AEDs with...

2014-07-11 08:24:53

MISSISSAUGA, ON, July 11, 2014 /CNW/ - Sunovion Pharmaceuticals Canada Inc. (Sunovion) today announced that Health Canada approved APTIOM(TM) (eslicarbazepine acetate) for use as a once-daily adjunctive therapy for the treatment of partial-onset seizures in patients with epilepsy who are not satisfactorily controlled with conventional therapy. APTIOM(TM) is not indicated for use in patients under 18 years of age. Epilepsy is one of the most common neurological disorders and...

2014-06-17 00:20:31

WOODCLIFF LAKE, N.J., June 16, 2014 /PRNewswire/ -- Eisai Inc. announced today that a Phase III clinical trial (study 332) of its in-house-discovered AMPA receptor antagonist perampanel has met its primary endpoint in patients with primary generalized tonic-clonic (PGTC) seizures, a severe form of seizures. http://photos.prnewswire.com/prnvar/20120413/MM87168LOGO Study 332 was a double-blind, randomized, placebo-controlled, multicenter, parallel-group trial to evaluate the efficacy and...

2014-04-25 08:27:40

WOODCLIFF LAKE, N.J., April 25, 2014 /PRNewswire/ -- Eisai Inc. announced today that six abstracts highlighting data analyses for FYCOMPA(TM) (perampanel) will be presented at the 66(th) annual American Academy of Neurology (AAN) meeting, taking place in Philadelphia, PA from April 26( )- May 3. http://photos.prnewswire.com/prnvar/20120413/MM87168LOGO "Eisai and its epilepsy franchise are committed to expanding its knowledge of current products and developing new medications for the...

2014-01-02 08:23:03

FYCOMPA is the First and Only FDA-Approved Non-Competitive AMPA Glutamate Receptor Antagonist WOODCLIFF LAKE, N.J., Jan. 2, 2014 /PRNewswire/ -- Eisai Inc. announced today that FYCOMPA(TM) (perampanel) CIII will be available to eligible patients by prescription in the U.S. beginning January 6, 2014. FYCOMPA is an adjunctive therapy for the treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy age 12 years and older. FYCOMPA is...

2013-11-04 10:36:26

Bipolar drugs lose effect during pregnancy, so women need higher doses to stay well New Northwestern Medicine® research offers one of the first in-depth studies of how physiological changes during pregnancy reduce the effects of a commonly used drug to treat bipolar disorder, making women more vulnerable to recurring episodes. The new findings will help psychiatrists and physicians prevent bipolar manic and depressive symptoms during pregnancy, which are risky for the health of the mother...


Word of the Day
monteith
  • A large punch-bowl of the eighteenth century, usually of silver and with a movable rim, and decorated with flutings and a scalloped edge. It was also used for cooling and carrying wine-glasses.
  • A kind of cotton handkerchief having white spots on a colored ground, the spots being produced by a chemical which discharges the color.
This word is possibly named after Monteith (Monteigh), 'an eccentric 17th-century Scotsman who wore a cloak scalloped at the hem.'
Related